Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00091923 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children
A Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
- 2
- Study locations
NCT00091923: Completed Phase 3 study of Amblyopia, sponsored by Jaeb Center for Health Research.
NCT00091923 is a Phase 3 study of Amblyopia that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 268 participants, above the 154-participant average among 24 other Amblyopia trials with a reported enrollment target (74% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00091923, a Phase 3 study of Amblyopia, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of the Spectacle Phase are: * In previously untreated pure anisometropic patients (i.e. patients who have not used spectacles in the last year and who do not have strabismus), to determine 1. the incidence of resolution of amblyopia with spectacle correction alone and 2. the time course of visual acuity improvement with spectacle correction alone. * In all other patients, to achieve maximal improvement with spectacle correction prior to entering the randomized trial. The objectives of the Randomized Trial are: * To determine whether 5 weeks of patching treatment (2 hours of patching per day of the sound eye combined with at least one concurrent hour of near activities), compared with a control group (using spectacle correction only), improves visual acuity in patients with moderate to severe amblyopia (20/40 to 20/400). * To determine the maximal improvement and time course of improvement with this patching treatment regimen.
Conditions Studied
Interventions
- DEVICE Spectacles
- DEVICE Eye patch
Study Locations (2)
California
- Southern California College of Optometry - Fullerton
North Carolina
- Duke University Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
What the finished NCT00091923 record still lists
NCT00091923 is an interventional study that assigns participants to a tested intervention. The registered 268 participants enrollment target is mid-sized for trials with a published cap, above the 154-participant average among 24 other Amblyopia trials with a reported enrollment target (74% higher).
The record links to 1 condition, with Amblyopia appearing as the primary indexed condition, and to 2 interventions - of which Spectacles is the first listed.
NCT00091923 reports a single indexed study location in California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00091923 about?
NCT00091923 is a clinical study titled "Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children". The objectives of the Spectacle Phase are: * In previously untreated pure anisometropic patients (i.e. patients who have not used spectacles in the last year and who do not have strabismus), to determine 1. the incidence of resolution of amblyopia with spectacle correction alone and 2. the tim...
What is the current status of trial NCT00091923?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2004-02. Estimated completion is 2005-12.
What conditions does trial NCT00091923 study?
This clinical trial studies the following conditions: Amblyopia.
What interventions are being tested in trial NCT00091923?
The interventions under investigation include: Spectacles (DEVICE), Eye patch (DEVICE).
Who is sponsoring clinical trial NCT00091923?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00091923 being conducted?
This trial has 2 study locations across California, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Amblyopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00091923's enrollment target sits among peer trials
268 4th of 24 higher than 21 of 24 other Amblyopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Amblyopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
RECRUITING · Phase 3
-
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
RECRUITING · Phase 3
-
Amblyopia (Lazy Eye) Treatment Study
COMPLETED · Phase 3
-
Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old
COMPLETED · Phase 3
-
Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000632 · 268 participants · NA
Smoke Free SafeCare: Establishing a Smoke Free Home in CPS-involved Families
- NCT05797831 · 268 participants · Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
- NCT05997381 · 268 participants · NA
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
- NCT06233461 · 268 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia